<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02224534</url>
  </required_header>
  <id_info>
    <org_study_id>D5130C00138</org_study_id>
    <nct_id>NCT02224534</nct_id>
  </id_info>
  <brief_title>Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction</brief_title>
  <acronym>HEALING-AMI</acronym>
  <official_title>High PlatElet Inhibition With TicAgrelor to Improve Left Ventricular RemodeLING in Patients With ST-segment ElevAtion Myocardial Infarction: the HEALING-AMI Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National University Heart Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Changwon Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gyeongsang National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the novel role of ticagrelor to improve long-term LV
      remodeling following ST-segment elevation myocardial infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators designed the HEALING-AMI study to compare the influence of ticagrelor (180
      mg loading and 90 mg twice daily maintenance) vs. clopidogrel (600 mg loading and 75 mg daily
      maintenance) on long-term left ventricular (LV) remodeling measured by 3D echocardiography in
      STEMI patients undergoing primary PCI.

      The primary objective of the HEALING-AMI study is to demonstrate the novel role of long-term
      ticagrelor therapy in reducing the risk of LV remodeling,. The secondary objectives are to
      reveal the cross-talk between platelet and inflammatory process in ST-segment elevation
      myocardial infarction (STEMI) patients. Moreover, this study will determine whether the high
      platelet inhibition by ticagrelor culminate the protection of infarcted myocardium.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LV remodeling index (%)</measure>
    <time_frame>Interval change between baseline and 6 months after the index events</time_frame>
    <description>Real time 3D-echocardiography data sets will be analyzed with available 4D-LV Analysis software (e.g. TomTec Imaging Systems, Unterschleisheim, Germany) in the core lab.
Left ventricular (LV) remodeling index: a relative change in LV end-diastolic volume (LVEDV) seen at 6-month follow-up compared with the baseline during admission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NT-proBNP level at 6 months</measure>
    <time_frame>6 months after the index events</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change of LVESVI, LVEDVI and LVEF</measure>
    <time_frame>Interval change between baseline and 6 months after the index events</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of adverse LV remodeling</measure>
    <time_frame>Interval change between baseline and 6 months after the index events</time_frame>
    <description>Adverse LV remodeling: a relative &gt; 20% increase in LVEDV seen at 6-month follow-up compared with the baseline during admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of platelet reactivity</measure>
    <time_frame>At the time of PCI, 3 days and 1 month after the events</time_frame>
    <description>Measured by VerifyNow P2Y12 assay</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Post-PCI angiographic perfusion indicators: TIMI flow grade, myocardial blush grade, corrected TIMI frame count</measure>
    <time_frame>Just after primary PCI</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>EKG change: ST-segment elevation resolution (%), complete ST-segment resolution</measure>
    <time_frame>Baseline, 60 minutes after the PCI.</time_frame>
    <description>complete ST-segment resolution: ST-segment resolution â‰¥70%</description>
  </other_outcome>
  <other_outcome>
    <measure>Level of hs-CRP</measure>
    <time_frame>At the time of PCI, 1 month and 6 months after the events</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding events based on BARC or PLATO definition</measure>
    <time_frame>6 months after the events</time_frame>
    <description>BARC definition for bleeding is defined as type 1, 2, 3 (3a, 3b and 3c), 4, and 5 (5a and 5b), according to the Bleeding Academic Research Consortium classification.
Type 1 (nuisance or superficial bleeding).
Type 2 (internal bleeding).
Type 3a (TIMI minor bleeding).
Type 3b (TIMI major bleeding).
Type 3c (life threatening bleeding).
Type 4 (CABG-related bleeding).
Type 5a (probable fatal bleeding).
Type 5b (definite fatal bleeding). Bleeding events pertaining to type 1 to 3a are considered as minor bleeding and those pertaining to type 3b to 5b as major bleeding.
PLATO definition for bleeding
Major life-threatening bleeding.
Other major bleeding.
Minor bleeding.
The case report form (CRF) collects the event history of bleeding during admission and at 1 month and 6 months. Occurrences of major, minor, and combined major and minor bleeding events will be compared between groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac MRI (Substudy): LV remodeling index</measure>
    <time_frame>Three days and 6 months after the events</time_frame>
    <description>Measured at A*STAR-NUS Clinical Imaging Research Centre, Singapore</description>
  </other_outcome>
  <other_outcome>
    <measure>Level of inflammatory markers (Substudy)</measure>
    <time_frame>During hospitalization and at 1 month after the events</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">326</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Ticagrelor and Clopidogrel.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients assigned to the TICA group have loading dose of ticagrelor 180 mg just after the randomization, and then ticagrelor 90 mg twice daily during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients assigned to the CLPD group have loading dose of clopidogrel 600 mg just after the randomization, and then clopidogrel 75 mg daily should be maintained during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose</description>
    <arm_group_label>Ticagrelor and Clopidogrel.</arm_group_label>
    <other_name>Brillinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older.

          -  First-time onset STEMI patients uneventfully treated with primary PCI within 12 hours
             of onset of symptom.

          -  Infarct-related artery with TIMI 0, 1, or 2 grade flow at the time of initial
             diagnostic angiography (before wire passage).

          -  proximal or mid-portion lesion of epicardial coronary artery.

        Exclusion Criteria:

          -  Previous history of myocardial infarction.

          -  Left bundle branch block on ECG at the time of screening.

          -  Cardiogenic shock at the time of randomization.

          -  Refractory ventricular arrhythmias or atrial fibrillation.

          -  New York Heart Association class IV congestive heart failure.

          -  Severe or malignant hypertension (SBP&gt; 180 and/or DBP&gt; 120 mmHg).

          -  Fibrinolytic therapy.

          -  History of hemorrhagic stroke.

          -  Intracranial neoplasm, arteriovenous malformation, or aneurysm.

          -  Ischemic stroke within 3 months prior to screening.

          -  Platelet count &lt; 100,000/mm3 or hemoglobin &lt; 10 g/dL.

          -  A need for oral anticoagulation therapy that cannot be safely discontinued for the
             duration of the study.

          -  Women who are known to be pregnant, have given birth within the past 90 days, or are
             breast-feeding.

          -  Unable to cooperate with protocol requirements and follow-up procedures.

          -  A history of P2Y12 receptor inhibitor pretreatment (at least prior 1 month).

          -  An increased risk of bradycardia.

          -  Concomitant therapy with a strong cytochrome P-450 3A inhibitor or inducer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongwhi Park, MD., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gyeongsang National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young-Hoon Jeong, MD.,PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gyeongsan National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongwhi Park, MD.,PhD.</last_name>
    <phone>+82-55-750-8059</phone>
    <email>angio2000@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young-Hoon Jeong, MD.,PhD.</last_name>
    <phone>+82-55-214-3721</phone>
    <email>goodoctor@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Bejing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yundai Chen, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <state>CHONRANAM-Do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Joon Hong, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Bundang</city>
        <state>Gyeongki-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong-Won Suh, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changwon Samsung Medical Center</name>
      <address>
        <city>Changwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ju Hyeon Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Chungju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sang Yeub Lee, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jang Hoon Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jae-Hyeong Park, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Korea</city>
        <zip>660-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yongwhi Park, MD.,PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young-Hoon Jeong, MD.,PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Won Kim, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eun-Seok Shin, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeong Su Kim, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Heart Centre</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2014</study_first_posted>
  <last_update_submitted>November 14, 2016</last_update_submitted>
  <last_update_submitted_qc>November 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gyeongsang National University Hospital</investigator_affiliation>
    <investigator_full_name>Yongwhi Park</investigator_full_name>
    <investigator_title>MD.,PhD.</investigator_title>
  </responsible_party>
  <keyword>ST elevation myocardial infarction.</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Left ventricular remodeling</keyword>
  <keyword>Platelet reactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

